Lamivudine
- Product NDC
- 57237-274
- 11-digit product format
- 572370274
- Labeler code
- 57237
- Product ID
- 57237-274_413db889-6bea-4815-b016-d619dba8029f
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine
- Dosage form
- SOLUTION
- Route
- ORAL
- Labeler
- Rising Pharma Holdings, Inc.
- Application
- ANDA077695
- Marketing category
- ANDA
- Marketing start
- 2016-11-21
- Substance
- LAMIVUDINE
- Active strength
- 10 mg/mL
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Lamivudine
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| LAMIVUDINE | 10 mg/mL |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 2T8Q726O95 |
| Rxcui | 199148 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 57237-274-24 | Lamivudine | 240 mL in 1 BOTTLE | SOLUTION | 240 | | 9 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 57237-274 | LAMIVUDINE SOLUTION [RISING PHARMA HOLDINGS, INC.] | 9 | Current NDC, Legacy NDC, 1 package rows | 20240420_bed2e227-8d36-40ea-bbbf-d8793bfda425.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 57237-274-24 | 57237027424 | 240 mL in 1 BOTTLE (57237-274-24) | 240 ml | 2016-11-21 | 0000-00-00 | No | No | Current |